Introduction of [Pathway MAP of MASH compounds] to accelerate your research

When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces human pathology and also allows your compound to be evaluated.


In this post you will find the appropriate model mouse for your compound and the results.


As a pioneer in the field of MASH/NASH, we have conducted more than 800 drug efficacy evaluation studies in the STAMTM mouse model and have evaluated many candidate drugs for the treatment of MASH/NASH.


Below you can see a Pathway map summarizing the [mechanism of action and disease pathway] for the drugs that have been evaluated in the STAMTM model.

* Compounds marked in red have been evaluated in our STAMTM model, while P2 and P3 markers indicate that they have progressed to Phase II and Phase III of clinical trials.


For example, the following is an example of a drug evaluation study with Belapectin, which has progressed to Phase III in the clinical trial.

Traber et al., PLOS ONE, 2013



For STAMTM mice, the disease uniformly progresses from Steatosis → MASH/NASH → Fibrosis → HCC, so you can set the most appropriate study period for your target depending on your needs.


In addition, you can compare the results of your compound with the data from the other compounds that have progressed to clinical trials, which would allow you to more effectively evaluate your compound.


Again, for non-clinical studies, it is important to select an appropriate mouse model that reproduces human pathology and allows your compound to be evaluated.


You can achieve this by partnering with a non-clinical CRO that can provide the optimal disease models and study plans for your compound evaluation.


We would be delighted if our extensive expertise could support you in your research.